Dr. Devika Gajria, MD

Dr. Gajria practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Gajria's NPI, 1821270703, was assigned on December 3, 2007. Dr. Gajria graduated from Feinberg School of Medicine in 2005. Dr. Gajria's Illinois license number on file is 125049714.

Dr. Gajria's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Gajria's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Gajria to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gajria practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Gajria's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dmand AI has Dr. Gajria's licenses on file in 4 states: Illinois, Florida, New York and New Jersey.

Dmand AI lists breast cancer among the conditions Dr. Gajria treats.

CMS data shows 442 Medicare services from Dr. Gajria across 2 procedure codes in 2024, all of them office visits, for 195 Medicare patients. Medicare paid $38,226 for them. Every service was in an office.

CMS counts 195 Medicare patients who saw Dr. Gajria in 2024. The largest group is 65 to 74, with 95 patients. 75% of them have cancer, and 75% have high cholesterol. 17% are also on Medicaid. Their average risk score is 1.63, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gajria's median patient age at 67, with 96% women.

In 2024, Dr. Gajria wrote 438 Medicare Part D claims for 125 patients. 84% of them were for generic drugs. CMS names the drug for 333 of them, across 6 drugs with 11 or more claims each, at $518,451 in total drug cost. In 2023, CMS named 400 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Gajria for performance year 2024, reported as part of a group. Dr. Gajria accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gajria as offering telehealth.

Dmand AI links 14 papers to Dr. Gajria, published from 2008 to 2024. 2011 was the busiest year, with 2. The most frequent topics are Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Alopecia. Dr. Gajria has published most often in Breast Cancer Res Treat. Dr. Gajria's most frequent co-authors are Tiffany A. Traina, MD, Clifford A. Hudis, MD and Larry Norton, MD.

CMS Open Payments shows 5 general payments to Dr. Gajria from 4 drug and device companies from 2016 to 2021. Consulting fees make up the largest share, 59% of the total. Merck Sharp & Dohme Corporation paid the most, $300.

Dr. Gajria graduated from Feinberg School of Medicine in 2005.

Dr. Gajria is in network with 11 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.